GO:0038100 nodal binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038100 nodal binding is a molecular function defined as binding to a nodal protein, a member of the transforming growth factor-beta superfamily.
• Nodal binding is mediated by extracellular and membrane-associated proteins such as Cripto, Cerberus, Tomoregulin-1, Nicalin and Nomo, which modulate Nodal signaling [1,2,3,5,7,8].
• The Nodal pre-helix loop is a key structural determinant for Cripto-1 binding, and antibodies targeting this region can block the interaction.
• Nodal binding proteins can act as antagonists (Cerberus, Tomoregulin-1, Nicalin/Nomo) or as coreceptors (Cripto) to fine-tune signaling output [1,7,8].
• NODAL/Activin signaling downstream of receptor binding shapes SMAD2 chromatin binding and transcriptional responses.
• Understanding nodal binding is relevant to cancer, developmental disorders, and stem cell biology, and can be studied using CRISPR knockout, point mutation, knock-in, and overexpression models.
Description
Nodal binding (GO:0038100) is a molecular function that describes the physical interaction between a protein and a nodal ligand, a member of the transforming growth factor-beta (TGF-beta) superfamily [1,2,3,5,7,8]. Nodal proteins are secreted signaling molecules that play critical roles in embryonic development, stem cell maintenance, and tissue homeostasis. The binding event is the first step in a cascade that can either promote or inhibit downstream signaling, depending on the binding partner. For researchers, nodal binding represents a focal point for understanding how extracellular cues are interpreted by cells and how dysregulation of this interaction contributes to disease [1,6,7,8]. The molecular function of nodal binding is executed by a diverse set of proteins. Some, like Cripto, act as coreceptors that facilitate Nodal binding to activin receptors ALK4 and ALK7 [2,5]. Others, such as Cerberus, Tomoregulin-1 (TMEFF1), and the Nicalin/Nomo complex, function as antagonists that sequester Nodal or its coreceptor, thereby inhibiting signaling [1,7,8]. Structural studies have revealed that the Nodal pre-helix loop is a critical epitope for Cripto-1 binding, and monoclonal antibodies targeting this loop can disrupt the interaction. These findings highlight the therapeutic potential of modulating nodal binding. Given the importance of nodal binding in development and disease, researchers require robust experimental models to dissect its mechanisms. CRISPR-based gene editing enables the creation of knockout, point-mutation, knock-in, and overexpression cell lines to study the precise roles of nodal binding partners. This article provides a comprehensive overview of nodal binding, its key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods.
nodal binding At A Glance
| GO ID | GO:0038100 |
|---|---|
| GO term | nodal binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to a nodal protein, a member of the transforming growth factor-beta superfamily. |
| Major function | Mediates physical interaction with Nodal ligands, modulating TGF-beta superfamily signaling. |
| Key binding partners | Cripto, Cerberus, Tomoregulin-1 (TMEFF1), Nicalin, Nomo |
| Subcellular location | Extracellular space, cell membrane |
| Related processes | Nodal signaling pathway, embryonic development, stem cell maintenance |
What Is GO:0038100?
According to the Gene Ontology, nodal binding (GO:0038100) is defined as the binding to a nodal protein, a member of the transforming growth factor-beta superfamily. In other words, it is the molecular function of physically interacting with a Nodal ligand, which is a secreted signaling molecule. This binding event is typically mediated by extracellular or membrane-associated proteins that either facilitate or inhibit Nodal signaling. The term encompasses interactions that occur in the extracellular space or at the cell membrane, and it is distinct from receptor binding or downstream signaling events.
Why Is nodal binding Important in Cell Biology?
Nodal binding is a critical molecular function because it governs the initial step of Nodal signaling, a pathway essential for embryonic development, left-right asymmetry, and stem cell pluripotency. Dysregulation of nodal binding has been implicated in various cancers, where aberrant Nodal signaling promotes tumor progression and metastasis. Moreover, nodal binding proteins such as Cripto are overexpressed in many cancers and are considered therapeutic targets. Understanding the structural and biochemical basis of nodal binding can inform the design of inhibitors or antibodies that block pathological signaling. Therefore, studying nodal binding is not only fundamental for developmental biology but also holds promise for translational medicine.
• Nodal binding initiates a key signaling cascade in embryonic development and stem cell maintenance [1,6].
• Cripto, a nodal coreceptor, is overexpressed in many cancers and promotes tumorigenesis [2,3,5].
• Cerberus acts as a nodal antagonist and can suppress nodal-mediated phenotypes.
• Tomoregulin-1 (TMEFF1) inhibits nodal signaling by binding to Cripto, highlighting a regulatory mechanism.
• Nicalin and Nomo form a complex that antagonizes Nodal signaling, affecting early development.
• The Nodal pre-helix loop is a target for monoclonal antibodies that block Cripto-1 binding.
• NODAL/Activin signaling influences SMAD2 chromatin binding and transcriptional responses.
• Nodal binding is relevant to left-right axis determination and congenital heart defects.
• Modulating nodal binding may offer therapeutic strategies for cancer and fibrotic diseases.
• CRISPR-based models enable precise interrogation of nodal binding partners in disease contexts.
Molecular Mechanism of nodal binding
Nodal Ligand Structure and Pre-Helix Loop
In simple terms: Nodal proteins have a special loop that acts like a key to fit into binding partners.
Nodal proteins are members of the TGF-beta superfamily and contain a conserved cysteine knot structure. The pre-helix loop is a solvent-exposed region that is critical for interaction with the coreceptor Cripto-1. Structural investigations using theoretical and experimental approaches have shown that the Nodal pre-helix loop adopts a specific conformation that facilitates binding to Cripto [2,3]. Synthetic fragments of Nodal corresponding to this region can bind Cripto, ALK7, and ALK4 with varying affinities, underscoring the importance of this loop in molecular recognition.
Cripto as a Coreceptor for Nodal Binding
In simple terms: Cripto acts as a docking station that helps Nodal bind to signaling receptors.
Cripto (TDGF1) is a glycosylphosphatidylinositol-anchored membrane protein that serves as a coreceptor for Nodal. It binds directly to Nodal and facilitates the formation of a signaling complex with activin receptors ALK4 and ALK7. Structural studies have characterized the Nodal-Cripto interface, revealing that the pre-helix loop of Nodal inserts into a hydrophobic pocket on Cripto [2,5]. This interaction is essential for downstream SMAD2/3 phosphorylation and transcriptional activation.
Antagonists of Nodal Binding: Cerberus, Tomoregulin-1, and Nicalin/Nomo
In simple terms: Some proteins block Nodal by grabbing it or its partner, preventing signaling.
Cerberus is a secreted antagonist that binds Nodal and prevents its interaction with receptors, thereby inhibiting nodal signaling and suppressing nodal-mediated phenotypes. Tomoregulin-1 (TMEFF1) is a transmembrane protein that directly binds to Cripto and inhibits nodal signaling, acting as a negative regulator. Nicalin and its binding partner Nomo form a complex that antagonizes Nodal signaling, likely by interacting with Nodal or its receptor complex. These examples illustrate the diversity of nodal binding proteins in modulating signaling output.
Antibody Targeting of Nodal Binding Interface
In simple terms: Lab-made antibodies can stick to Nodal's key loop and stop it from binding Cripto.
Monoclonal antibodies have been developed against the Nodal pre-helix loop, which is involved in Cripto-1 binding. These antibodies can block the Nodal-Cripto interaction and inhibit downstream signaling. This approach demonstrates the therapeutic potential of targeting nodal binding interfaces and provides tools for probing the structural requirements of the interaction.
Regulation of Nodal Binding by Extracellular Modulators
In simple terms: Other molecules outside the cell can tweak how well Nodal binds to its partners.
The binding of Nodal to its partners is regulated by the availability of coreceptors and antagonists in the extracellular milieu. For instance, Cerberus competes with Cripto for Nodal binding, while Tomoregulin-1 sequesters Cripto. Additionally, morphogen transport mechanisms can influence the distribution and concentration of Nodal, thereby affecting binding events. These regulatory layers ensure precise control of Nodal signaling during development and tissue homeostasis.
Key Genes Involved in GO:0038100 nodal binding
The following genes encode proteins that directly bind Nodal or modulate nodal binding, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NODAL | Ligand; member of TGF-beta superfamily | Central to nodal binding; mutations cause developmental defects |
| CRIPTO (TDGF1) | Coreceptor for Nodal; facilitates receptor binding | Overexpressed in cancers; target for therapeutic antibodies |
| CER1 (Cerberus) | Secreted antagonist; binds Nodal and prevents receptor interaction | Inhibits nodal signaling; potential tumor suppressor |
| TMEFF1 (Tomoregulin-1) | Transmembrane antagonist; binds Cripto and inhibits nodal signaling | Negative regulator; implicated in neurodevelopment |
| NCLN (Nicalin) | Component of Nicalin/Nomo complex; antagonizes Nodal signaling | Regulates early embryonic development |
| NOMO1 (Nomo) | Binding partner of Nicalin; forms antagonist complex | Modulates Nodal signaling in development |
| ALK4 (ACVR1B) | Type I receptor for Nodal; binds Nodal-Cripto complex | Mediates downstream SMAD2/3 activation |
| ALK7 (ACVR1C) | Type I receptor for Nodal; alternative receptor | Involved in metabolic and developmental signaling |
| SMAD2 | Downstream effector; phosphorylated upon Nodal signaling | Transcription factor; chromatin binding shapes response |
| SMAD3 | Downstream effector; partners with SMAD2 | Mediates transcriptional responses |
| FOXH1 | Transcription factor; interacts with SMAD2/3 | Activates Nodal target genes |
| LEFTY1 | Secreted antagonist; feedback inhibitor of Nodal | Regulates left-right asymmetry |
| LEFTY2 | Secreted antagonist; feedback inhibitor of Nodal | Regulates left-right asymmetry |
| GDF1 | Co-ligand; forms heterodimers with Nodal | Enhances Nodal signaling |
| GDF3 | Co-ligand; modulates Nodal signaling | Involved in stem cell pluripotency |
| TDGF1P3 | Pseudogene; may regulate Cripto expression | Potential regulatory role in cancer |
| ACVR2A | Type II receptor; binds Nodal ligands | Initiates signaling cascade |
| ACVR2B | Type II receptor; binds Nodal ligands | Initiates signaling cascade |
How Is nodal binding Regulated?
Nodal binding is regulated at multiple levels. Extracellular antagonists such as Cerberus, Tomoregulin-1, and the Nicalin/Nomo complex directly compete with or sequester Nodal or its coreceptor Cripto, thereby inhibiting binding [1,7,8]. The availability of Cripto at the cell membrane is controlled by its glycosylphosphatidylinositol anchor and shedding. Additionally, morphogen transport mechanisms can alter the local concentration of Nodal, affecting binding kinetics. Intracellularly, feedback loops involving LEFTY1/2 and SMAD2/3 modulate the expression of nodal binding partners. These regulatory layers ensure that nodal binding occurs with spatial and temporal precision.
nodal binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CRIPTO (TDGF1) | Cancer (breast, melanoma, pancreatic) | CRISPR knockout and overexpression in cancer cell lines |
| NODAL | Heterotaxy, congenital heart defects | Knock-in of patient mutations in iPSCs |
| TMEFF1 | Neurodevelopmental disorders | Knockout in neuronal progenitor cells |
| NCLN | Embryonic lethality, developmental defects | Conditional knockout in mouse models |
| CER1 | Cancer, developmental anomalies | Overexpression in tumor cell lines |
Nodal Binding in Cancer
Aberrant Nodal signaling is implicated in various cancers, including melanoma, breast, and pancreatic cancer. Cripto (TDGF1), a key nodal binding coreceptor, is overexpressed in many tumors and correlates with poor prognosis. Targeting the Nodal-Cripto interaction with monoclonal antibodies or small molecules has shown promise in preclinical studies [2,3,5]. Cerberus, a Nodal antagonist, can suppress Nodal-mediated phenotypes, suggesting a tumor-suppressive role. Therefore, nodal binding is a potential therapeutic target in oncology.
Nodal Binding in Developmental Disorders
Nodal signaling is essential for left-right axis determination, and mutations in components of the nodal binding complex can cause congenital heart defects and situs inversus. For example, mutations in NODAL, CRIPTO, or LEFTY genes are associated with heterotaxy syndromes. Tomoregulin-1 (TMEFF1) and Nicalin/Nomo regulate Nodal signaling during embryogenesis, and their dysfunction may contribute to developmental anomalies [7,8]. Studying nodal binding helps elucidate the molecular basis of these disorders.
Nodal Binding in Stem Cell Biology and Regenerative Medicine
Nodal signaling maintains pluripotency in human embryonic stem cells and influences differentiation. Cripto is a marker of pluripotent cells and modulates Nodal signaling to balance self-renewal and differentiation [2,5]. Understanding nodal binding is crucial for optimizing stem cell culture conditions and for directed differentiation protocols in regenerative medicine. Moreover, CRISPR-based editing of nodal binding partners can create disease models for drug screening.
From nodal binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CRIPTO affect Nodal signaling and tumor growth? | CRIPTO knockout cancer cell lines |
| How do point mutations in NODAL pre-helix loop affect Cripto binding? | Point-mutation knock-in cell lines |
| Can tagged Cripto be used to track Nodal binding dynamics? | Knock-in of fluorescent tags (e.g., GFP) at CRIPTO locus |
| What is the effect of Cerberus overexpression on Nodal signaling? | Overexpression of CER1 in stem cells or cancer cells |
| Does TMEFF1 knockout alter neuronal differentiation? | TMEFF1 knockout in iPSC-derived neurons |
| How does Nicalin/Nomo complex regulate Nodal during development? | Knockout of NCLN or NOMO1 in zebrafish or mouse embryos |
How to Study the nodal binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Measure Nodal-Cripto interaction |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | Validate binding constants |
| X-ray crystallography | 3D structure of protein complexes | Determine Nodal-Cripto interface |
| Molecular dynamics simulation | Conformational dynamics | Model pre-helix loop flexibility |
| Luciferase reporter assay | SMAD2/3 transcriptional activity | Assess functional impact of binding |
| Western blot | Phosphorylated SMAD2 levels | Quantify pathway activation |
| CRISPR knockout screen | Genes affecting Nodal signaling | Identify novel regulators |
Biochemical Binding Assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure the affinity and kinetics of Nodal binding to partners such as Cripto, Cerberus, or Tomoregulin-1. These methods provide quantitative data on binding constants and are essential for validating structural models [1,2,5].
Structural Biology and Computational Modeling
X-ray crystallography, NMR, and molecular dynamics simulations can elucidate the atomic details of the Nodal-Cripto interface. Theoretical and experimental approaches have been combined to investigate the Nodal-Cripto binding, revealing the importance of the pre-helix loop [2,3,5]. These methods guide the design of inhibitors.
Cell-Based Signaling Assays
Luciferase reporter assays for SMAD2/3 activation, Western blotting for phosphorylated SMAD2, and immunofluorescence for SMAD nuclear translocation are used to assess the functional consequences of nodal binding. These assays can be performed in CRISPR-edited cell lines to test the role of specific binding partners.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that modulate Nodal signaling. By using a Nodal-responsive reporter, researchers can uncover novel regulators of nodal binding and signaling. This approach is powerful for discovering therapeutic targets.
How CRISPR Can Be Used to Study GO:0038100 nodal binding
Knockout
CRISPR knockout of nodal binding partners such as CRIPTO, CER1, or TMEFF1 can reveal their essential roles in Nodal signaling. For example, CRIPTO knockout cells show reduced SMAD2 phosphorylation and altered differentiation potential [2,5]. Knockout models are valuable for validating drug targets and understanding loss-of-function phenotypes.
Point Mutation
Introducing point mutations in the Nodal pre-helix loop or in the Cripto binding pocket can dissect the structural requirements for binding. For instance, mutations that disrupt the pre-helix loop abolish Cripto binding and downstream signaling [3,5]. Point-mutation cell lines are ideal for structure-function studies.
Knock-in
Knock-in of epitope tags (e.g., HA, FLAG) or fluorescent proteins (e.g., GFP) at endogenous loci allows real-time tracking of nodal binding proteins. Tagged Cripto or Nodal can be used for co-immunoprecipitation and imaging studies to visualize binding dynamics in live cells [2,6].
Overexpression
Overexpression of nodal binding proteins such as Cerberus or Tomoregulin-1 can suppress Nodal signaling and reverse disease phenotypes. Overexpression models are useful for gain-of-function studies and for testing therapeutic candidates [1,7]. Conversely, overexpression of Cripto can enhance Nodal signaling and promote tumorigenesis [2,3].
How EDITGENE Supports nodal binding Research
Researchers studying nodal binding-related genes often need to determine whether a candidate gene is causally involved in signaling, development, or disease. This requires precise genetic manipulation to create isogenic models that differ only at the locus of interest. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such investigations, from knockout to knock-in and beyond.
Contact EDITGENE today to design your custom CRISPR model for nodal binding research.
Frequently Asked Questions About nodal binding
What is nodal binding?
Nodal binding (GO:0038100) is the molecular function of binding to a nodal protein, a member of the TGF-beta superfamily. It is the first step in Nodal signaling and is mediated by proteins such as Cripto, Cerberus, and Tomoregulin-1 [1,2,3,5,7,8].
What genes are involved in nodal binding?
Key genes include NODAL, CRIPTO (TDGF1), CER1 (Cerberus), TMEFF1 (Tomoregulin-1), NCLN (Nicalin), and NOMO1 (Nomo). These encode proteins that directly bind Nodal or modulate its interactions [1,2,3,5,7,8].
How does nodal binding regulate signaling?
Nodal binding can either promote signaling, as with the Cripto coreceptor, or inhibit it, as with antagonists like Cerberus and Tomoregulin-1. The balance determines downstream SMAD2/3 activation and transcriptional responses [1,2,6,7].
What diseases are associated with nodal binding?
Dysregulated nodal binding is implicated in cancer (e.g., breast, melanoma), developmental disorders such as heterotaxy, and stem cell-related pathologies [1,2,3,5,7,8].
What is the role of Cripto in nodal binding?
Cripto is a coreceptor that binds Nodal and facilitates its interaction with activin receptors ALK4 and ALK7, thereby promoting signaling. It is overexpressed in many cancers [2,3,5].
How can I study nodal binding in the lab?
Common methods include surface plasmon resonance, isothermal titration calorimetry, structural biology, cell-based signaling assays, and CRISPR-based genetic screens [1,2,3,5,6].
What CRISPR models are available for nodal binding research?
EDITGENE offers knockout, point mutation, knock-in (tagged), and overexpression cell models for nodal binding genes, as well as CRISPR library screening and bioinformatics services.
What is the Nodal pre-helix loop?
The Nodal pre-helix loop is a structural region critical for binding to Cripto-1. Antibodies targeting this loop can block the interaction and inhibit signaling [3,5].
How does Cerberus inhibit nodal signaling?
Cerberus binds Nodal directly and prevents it from interacting with receptors, thereby inhibiting nodal signaling and suppressing nodal-mediated phenotypes.
What is the role of Tomoregulin-1 in nodal binding?
Tomoregulin-1 (TMEFF1) binds to the Nodal coreceptor Cripto and inhibits nodal signaling, acting as a negative regulator.
Conclusion
Nodal binding (GO:0038100) is a fundamental molecular function that governs the initial step of Nodal signaling, a pathway critical for development and disease. The interaction between Nodal and its binding partners, such as Cripto, Cerberus, Tomoregulin-1, and Nicalin/Nomo, is finely regulated and offers numerous targets for therapeutic intervention. Understanding the structural and biochemical basis of nodal binding can inform the design of inhibitors and antibodies for cancer and developmental disorders. With advanced CRISPR tools and screening platforms, researchers can now dissect nodal binding with unprecedented precision, accelerating discoveries in developmental biology and oncology.
References
- 1. Aykul S et al.. 2015. Human Cerberus prevents nodal-receptor binding, inhibits nodal signaling, and suppresses nodal-mediated phenotypes.. PLoS One 10(1):e0114954 PMID: 25603319
- 2. Calvanese L et al.. 2010. Structural investigations on the Nodal-Cripto binding: a theoretical and experimental approach.. Biopolymers 93(11):1011-21 PMID: 20629020
- 3. Focà A et al.. 2015. New Anti-Nodal Monoclonal Antibodies Targeting the Nodal Pre-Helix Loop Involved in Cripto-1 Binding.. Int J Mol Sci 16(9):21342-62 PMID: 26370966
- 4. Müller P et al.. 2013. Morphogen transport.. Development 140(8):1621-38 PMID: 23533171
- 5. Calvanese L et al.. 2015. Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments.. J Pept Sci 21(4):283-93 PMID: 25588905
- 6. Coda DM et al.. 2017. Distinct modes of SMAD2 chromatin binding and remodeling shape the transcriptional response to NODAL/Activin signaling.. Elife 6 PMID: 28191871
- 7. Harms PW et al.. 2003. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto.. Genes Dev 17(21):2624-9 PMID: 14563676
- 8. Haffner C et al.. 2004. Nicalin and its binding partner Nomo are novel Nodal signaling antagonists.. EMBO J 23(15):3041-50 PMID: 15257293
